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Disclaimer
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and 
peer-reviewed literature available at the time they are written, and are intended only to assist clinicians in decision-making, as well as 
to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. 
Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not 
account for all individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of 
other treatments. It remains the responsibility of the health care provider to determine the best course of treatment for the patient. 
Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the clinician 
and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC’s 
guidelines, or for any errors or omissions.
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Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large inter-
patient variability partly due to genetic variations in CYP2C9. Furthermore, the variant allele 
HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic 
epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the 
published literature supporting these associations and provide recommendations for the use of 
phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: 
www.pharmgkb.org).
Keywords
Phenytoin; HLA-B; CPIC; CYP2C9; pharmacogenetics; fosphenytoin; Stevens-Johnson 
syndrome; toxic epidermal necrolysis
Introduction
The purpose of this guideline is to provide information for the interpretation of HLA-B 
and/or CYP2C9 genotype tests so that the results can guide dosing and/or use of phenytoin. 
Detailed guidelines for use of phenytoin as well as analyses of cost effectiveness are out of 
scope. CPIC guidelines are periodically updated at http://www.pharmgkb.org.
Focused Literature Review
A literature review focused on CYP2C9 and HLA-B*15:02 genotype and phenytoin use (see 
Supplemental Material online) was conducted. Reviews were included to summarize the 
available literature.
Genes: HLA-B and CYP2C9
Background
In this guideline, human leukocyte antigen B (HLA-B) will be discussed as it relates to 
phenytoin-induced cutaneous adverse drug reactions (ADRs) of Stevens-Johnson syndrome 
(SJS) and toxic epidermal necrolysis (TEN) and hepatic CYP2C9 and its alleles are 
discussed as they relate to phenytoin metabolism and dosing.
HLA-B—HLA-B is part of a gene cluster designated as the human major histocompatibility 
complex (MHC) located on the short arm of chromosome 6. The cluster contains three 
classes (I, II and III). MHC class I contains three genes: HLA-B plus HLA-A and HLA-C. 
HLA-B encodes a cell surface protein that binds peptides generated by proteolysis and 
extruded from proteasomes. The presentation of these peptides on the cell surface enables 
the immune system to distinguish self-proteins from foreign proteins typically introduced by 
infectious organisms (e.g., viruses and bacteria) (see supplemental material for further 
discussion).
HLA genes, and specifically HLA-B, are among the most highly polymorphic genes in the 
human genome. HLA polymorphisms were previously ascertained serologically, but 
genotyping and DNA sequencing methods reveal much greater genetic complexity. More 
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than 2,000 HLA-B alleles, many of which differ by more than one nucleotide from each 
other, were deposited to the World Health Organization (WHO) Nomenclature Committee 
for Factors of the HLA System (http://hla.alleles.org). Each allele is designated by the gene 
name followed by an asterisk and up to an eight-digit (four pairs) identifier giving 
information about the allele type (designated by the first two digits) and specific protein 
subtypes (second set of digits). For more information and a diagram outlining the 
description of the current HLA allele nomenclature see http://hla.alleles.org/nomenclature/
naming.html. The details of HLA nomenclature are also described in a previous CPIC 
guideline (1). This guideline specifically discusses only the HLA-B*15:02 allele as it relates 
to the phenytoin-induced cutaneous adverse drug reactions of SJS and TEN.
CYP2C9—Hepatic CYP2C9 enzyme contributes to the metabolism of many clinically 
relevant drugs, including phenytoin (http://www.pharmgkb.org/pathway/PA145011115). 
The CYP2C9 gene is highly polymorphic, having more than 50 known variant alleles (http://
www.cypalleles.ki.se/cyp2c9.htm, Supplemental Table S1 and S2). Individuals homozygous 
for the reference CYP2C9 allele (CYP2C9*1) have the “normal metabolizer” phenotype. 
Each named CYP2C9 star (*) allele is defined by a genotype at one or more specific single-
nucleotide polymorphisms (SNPs) with variable enzyme activity. The two most common 
variants with reduced enzyme activity in Europeans are CYP2C9*2 (rs1799853) and 
CYP2C9*3 (rs1057910) (2).
Genetic Test Interpretation
HLA-B—Clinical genotyping test results for HLA-B*15:02 are interpreted as “positive” if 
one or two copies of HLA-B*15:02 are present or “negative” if no copies of HLA-B*15:02 
are present. Phenotype assignments for HLA-B*15:02 genotypes are summarized in Table 1. 
The allele frequencies of HLA-B vary greatly among populations. Specifically, HLA-
B*15:02 is most prevalent in Oceania, East Asian and South/Central Asian populations 
ranging from 1% to over 10%. It is less frequent in European populations (0–1%) and 
apparently absent in several African populations (Supplemental Table S3 and S4). The 
global average derived from over 46,000 individuals is 1.37%.
CYP2C9—Most clinical laboratories reporting CYP2C9 genotype use the star (*) allele 
nomenclature and may interpret the patient’s predicted metabolizer phenotype (Table 1, 
Supplemental Table S1). The combination of alleles is used to determine a patient’s 
diplotype. Not all CYP2C9 allelic variants may be tested, influencing the accuracy of the 
genotype-based dose prediction, primarily in individuals of Asian or African ancestry who 
carry other common functionally decreased activity CYP2C9 variant alleles (Supplemental 
Table S5). The frequencies of the CYP2C9 *2 and *3 alleles and diplotypes derived from 
these and other alleles differ between racial/ethnic groups (Supplementary Table S5, S6 and 
S7) (2). CYP2C9 alleles are typically characterized as wild-type (normal function) or 
decreased function depending on the reported activity of the enzyme for which they encode.
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Available Genetic Test Options
Several methods of CYP2C9 and HLA-B genotyping are commercially available. The 
Supplemental Material online and at www.pharmgkb.org contains more information on 
available clinical testing options.
Incidental findings
HLA-B alleles are associated with hypersensitivity reactions to other drugs. CPIC guidelines 
are available for HLA-B*57:01 and abacavir-induced hypersensitivity reactions, HLA-
B*58:01 and allopurinol-induced severe cutaneous adverse reactions, and HLA-B*15:02 
and carbamazepine-induced SJS and TEN (1, 3, 4).
No diseases have been linked to genetic variations in CYP2C9, except for a small study that 
linked CYP2C9*2 and *3 variants and phenytoin to a higher frequency of cerebellar atrophy 
(5). CYP2C9 poor metabolizers may be predisposed to serious bleeding during warfarin 
therapy (6).
Other Considerations
Not applicable
Drugs: Phenytoin and Fosphenytoin
Phenytoin and its prodrug fosphenytoin are one of the mainstays of treatment for both focal 
and generalized convulsive status epilepticus. Dosing is complex owing to its highly unusual 
pharmacokinetics and requiring adjustments be made in line with patient weight, sex, and 
age. Outpatient therapy is generally initiated at 5–7 mg/kg/day in adults (slightly higher in 
children) and may be given once daily (or twice daily in children). Starting dose must be 
lower in the setting of hepatic impairment. Careful dose adjustments must then be made -- 
generally 30 – 40 mg at a time in 2-week intervals in adults -- to stabilize the level within 
the typical therapeutic range (10 – 20 ug/dL). In urgent situations such as status epilepticus, 
intravenous loading doses of 15–20 mg/kg are given, followed by maintenance doses, IV or 
oral, as above. Acute dose-related side effects include sedation, ataxia, dizziness, nystagmus, 
nausea, and cognitive impairment. The drug is highly allergenic, and rashes ranging from 
mild eruptions to life-threatening hypersensitivity reactions may be seen. HLA-B*15:02 is 
associated with the phenytoin-induced SJS and TEN. SJS is characterized by epidermal 
detachment involving up to 10% of body surface area (BSA) while TEN usually affects 
more than 30% of the BSA. Subacutely, hematologic and hepatic toxicity can occur; the 
latter is likely a hypersensitivity reaction itself, as it is usually accompanied by rash (7), 
while the former may consist of leukopenia or pancytopenia.
Because of the acute dose-related side effects, initial maintenance dose selection is 
important. Higher plasma concentrations increase the probability of these toxicities. 
However, non-linear saturable pharmacokinetics, auto-inductive effects with maintenance 
dosing, and CYP2C9 pharmacogenetic polymorphisms complicate dose-selection. The 
CYP2C9 poor metabolizer phenotype and CYP2C9 drug interactions, such as produced by 
voriconazole, can significantly augment phenytoin exposure (8). Variability in protein 
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binding, primarily related to changes in albumin concentrations, can confound the 
relationship of therapeutic drug monitoring and pharmacodynamic expectations. Further 
discussion of the metabolism of phenytoin and fosphenytoin can be found in the 
supplemental material.
Linking genetic variability to variability in drug-related phenotypes
Substantial evidence links CYP2C9 and HLA-B*15:02 genotype with phenotypic variability 
(see Supplemental Tables S8 and S9). Application of a grading system to evidence linking 
genotypic to phenotypic variability indicates a high quality of evidence in the majority of 
cases (Supplemental Tables S8 and S9). The evidence presented here and in Supplemental 
Tables S8 and S9 provides the basis for the dosing recommendations in Table 2.
HLA-B—An increased risk of SJS/TEN has been associated with the HLA-B*15:02 allele 
in Han Chinese and other Asian groups (see Supplemental Material; Supplemental Table 
S8). Cheung et al conducted a meta-analysis of two studies in Taiwan (9) and Hong Kong 
(10), comprising in total 41 cases and 188 controls and showed a positive association of 
HLA-B*15:02 with phenytoin-induced SJS/TEN (p < 3 × 10−4; OR 4.26; 95% CI 1.93–
9.39) under a fixed-effect model with statistically insignificant heterogeneity. By pooling 
data directly, the association had a sensitivity of 36.6% (95% CI 23.6–51.9) and specificity 
of 87.2% (95% CI 81.7–91.3). Therefore, the absence of these variants does not rule out the 
possibility of a patient developing phenytoin-induced SJS/TEN. The strength of the 
association between phenytoin use and SJS/TEN is weaker than the association between 
carbamazepine use and SJS/TEN due to the limited number of studies and observations with 
phenytoin or fosphenytoin in the literature. However, taken together with the known 
association of carbamazepine and SJS/TEN in carriers of HLA-B*15:02 the association 
supports the FDA recommendations to avoid these agents as substitutes for carbamazepine 
in individuals who test positive for HLA-B*15:02 (4).
CYP2C9—Available model estimates predict that variant CYP2C9 alleles lower phenytoin 
intrinsic clearance based on the allele and number of variant. Several studies indicate that 
individuals with CYP2C9*1/*3 and CYP2C9*1/*2 genotypes have mild-to-moderately 
reduced clearance values (Supplemental Table S9) and are classified as Intermediate 
Metabolizers. Individuals with two decreased activity alleles (CYP2C9*2/*2, 
CYP2C9*3/*3) have reduced clearance of several drugs and are classified as CYP2C9 poor 
metabolizers. Phenytoin maintenance doses were reported to be reduced 23–38% in 
heterozygous individuals with one decreased activity allele (11–13) and 31–52% for carriers 
with two decreased activity CYP2C9 alleles versus CYP2C9*1/*1 (12, 13). Furthermore, 
case reports indicate that poor metabolizers appear to be at higher risk for exposure-related 
toxicities than patients homozygous for the wild-type alleles (14–17).
Therapeutic Recommendations
HLA-B*15:02 recommendations—The FDA warning for phenytoin states, 
“Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in 
patients positive for HLA-B*15:02″ due to the increased risk of SJS/TEN in patients of 
Asian ancestry.” The evidence linking HLA-B*15:02 to phenytoin-induced SJS/TEN was 
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generated in individuals of Asian ancestry as the frequency of HLA-B*15:02 is very low in 
other populations (see Supplemental Table S3 and S4 for frequency information) that have 
been studied. However, it may also occur in other populations throughout the world yet to be 
studied and patients may be unaware of or fail to disclose more distant Asian ancestry in 
their families. Furthermore, much of the evidence (summarized in Supplemental Table S8) 
linking HLA-B*15:02 to phenytoin-induced SJS/TEN was generated in both children and 
adults. Therefore, regardless of the CYP2C9 genotype and individual’s ancestry or age, if 
the HLA-B*15:02 test result is “positive”, the recommendation is to consider using an 
anticonvulsant other than carbamazepine and phenytoin unless the benefits of treating the 
underlying disease clearly outweigh the risks (see Table 2). Alternative medications such as 
oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking 
SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing 
alternatives to phenytoin (see Supplement for details).
CYP2C9 recommendations—Phenytoin and fosphenytoin dose should first be adjusted 
according to a patient’s clinical characteristics. Table 2 summarizes the gene-based dosing 
recommendations for phenytoin based on CYP2C9 phenotype. The recommended phenytoin 
maintenance dose does not need adjustment based on genotype for CYP2C9 extensive 
metabolizers. Available evidence does not clearly indicate the amount of dose reduction 
needed to prevent phenytoin-related toxicities in CYP2C9 intermediate and poor 
metabolizers; thus, our recommendation should be considered conservative estimates given 
the variability surrounding phenytoin dosing to an individual. Based on the doses reported in 
the pharmacokinetic and pharmacogenetic studies mentioned above (11–13) and in 
Supplemental Table S9, at least a 25% reduction of the recommended starting maintenance 
dose may be considered for CYP2C9 intermediate metabolizers with subsequent 
maintenance doses adjusted based on therapeutic drug monitoring and response. For 
CYP2C9 poor metabolizers, consider at least a 50% reduction of starting maintenance dose 
with subsequent maintenance doses adjusted based on therapeutic drug monitoring or 
response.
Furthermore, while in vitro data suggest that the degree of reduction of catalytic activity is 
greater for the CYP2C9*3 variant than for the CYP2C9*2 variant (18), clinical 
pharmacokinetic studies indicate similar dose reductions and pharmacokinetic parameters 
(e.g., trough levels, serum p-HPPH/P ratio) for these variants as compared to wild-type (12, 
19, 20). Thus, our recommendation is to start with at least the above recommended reduction 
of the maintenance dose followed by an adjustment of dose based on therapeutic drug 
monitoring.
Pediatrics—Special consideration should be taken with the pediatric population. 
Phenytoin is used in the treatment of neonatal seizures and subsequently after discharge 
from the neonatal ICU. Maintaining therapeutic levels can be particularly problematic in this 
population. This may be due to the developmental expression of hepatic CYP2C. P450 
expression and functional activities have been shown to develop at different rates within 
subfamilies (21). It has been found that activity levels of CYP2C9 are at 1 to 2% of adult 
values in the fetus during the first trimester. These levels gradually increase to 30% of adult 
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values at term. There is a high variability in these levels during the first five months of life, 
eventually approach adult values somewhere between five months to 2 years of age (22). 
Other considerations includethe clearance of phenytoin being twice that of adult values in 
children under 6 years of age. This is attributed to the finding that the maximal rate of 
phenytoin metabolism is inversely related to age. However, this varied significantly within 
age subgroups (23). For these reasons, phenytoin therapeutic recommendations based on 
CYP2C9 genotype in this population are difficult. There is only one published report 
describing a two-year old patient (CYP2C9*2/*2 and CYP2C19*1/*4) presenting with 
phenytoin toxicity two hours after a 15mg/kg phenytoin loading dose with symptoms lasting 
122 hours (24). The half-life was much higher than expected (112 hours versus 46.7) which 
could be explained by the influence of CYP2C9 and CYP2C19 genetic polymorphisms 
(other predisposing factors such as malnourishment, renal failure, hepatic dysfunction, and 
inhibition of phenytoin metabolism by other drugs were ruled out). Therefore, for pediatric 
patients who are CYP2C9 intermediate or poor metabolizers dose adjustment is 
recommended with close therapeutic drug monitoring.
HLA-B*15:02 and CYP2C9 dosing recommendation—If both HLA-B*15:02 and 
CYP2C9 genotype are known, consider the HLA-B*15:02 genotype first, then the CYP2C9 
genotype (Figure 1; Table 2).
Other considerations
HLA-B—HLA-B*15:02 is linked to SJS and TEN but not to a predisposition for other 
phenytoin-induced cutaneous adverse reactions such as mild maculopapular eruptions 
(MPE) or drug hypersensitivity syndrome (HSS) (25).
CYP2C9—Because of its potent CYP450-inducing properties, phenytoin is involved in a 
very large number of drug interactions, especially involving increased metabolism of other 
agents with subsequent decrease in their levels (26). A full discussion of these is beyond the 
scope of this guideline, but agents prominently and significantly affected include 
antineoplastic and immunosuppressive agents, lipid-lowering agents, psychotropics, oral 
contraceptives, and warfarin, just to name a few. Furthermore, inhibitors of CYP2C9 can 
generate phenytoin overexposure and toxicity. Although fluconazole and amiodarone are 
recognized as potent CYP2C9 enzyme inhibitors, other less potent drugs can produce 
significant elevations in phenytoin plasma concentrations. Therefore, it is important to 
interpret the results of genetic testing in the context of other co-administered drugs.
CYP2C9 genetic variation does not account for all of the pharmacogenetic variability in 
phenytoin metabolism. Some studies have implicated variants in other genes associated with 
phenytoin metabolism (e.g., CPY2C19, CYP1A1, and EPHX1; see (27) for a review) and 
combined genetic analysis might improve the predictability of CYP2C9 alone (11, 13). 
However, this has not been consistently replicated and there are limited studies evaluating 
the effect of multiple gene variation and phenytoin dose adjustment requirement. 
Consequently, this guideline on genotype-directed phenytoin dosing is limited to CYP2C9 
variant alleles.
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Recommendations for Incidental Findings
Several drugs structurally and therapeutically similar to phenytoin, such as oxcarbazepine 
and carbamazepine, have also been associated with SJS/TEN and HLA-B*15:02 in Asian 
populations (28–34) (see Supplemental Material). The drug-specific evidence linking HLA-
B*15:02 and SJS/TEN is discussed in the CPIC Guideline for HLA-B genotype and 
carbamazepine dosing (4) and may have implications for choosing alternatives to phenytoin 
in those who carry the HLA-B*15:02 allele. Case reports have identified cross-reactions to 
lamotrigine and other anti-epileptic drugs in the presence of HLA-B*15:02 (see 
Supplemental Material for further discussion). However, larger studies appear to be needed 
for confirmation.
CYP2C9 metabolism includes substrates from several drug classes, including NSAIDS, oral 
hypoglycemics/sulfonylureas, as well as a miscellaneous group of drugs. Reports support 
that patients with enhanced sensitivity to warfarin are likely to have a decreased capacity to 
metabolize phenytoin (35).
Potential Benefits and Risks for the Patient
The potential benefit for patients with existing CYP2C9 and/or HLA-B*15:02 genotyping 
information is in avoiding adverse effects in those patients who are CYP2C9 poor 
metabolizers by making significant reductions in their starting maintenance dose or by 
selecting alterative agents for those who are HLA-B*15:02 carriers. For HLA-B*15:02 
carriers, a potential risk is that phenytoin therapy may have been needlessly avoided in 
patients who may not have developed SJS/TEN; however, this risk is mitigated because 
alternatives to phenytoin with comparable effectiveness exist. Another potential risk would 
be an error in genotyping. Also, many commercially available genotyping tests do not detect 
alleles that are rare or de novo variants. Other alleles are not well characterized, resulting in 
uncertainty when predicting the phenotype for some genetic test results. Due to the high rate 
of HLA-B*15:02 false-negative results (36) or in the event of a rare variant not detected on 
the genetic test,, a high-risk patient could be prescribed phenytoin or prescribed a higher 
dose than needed. Moreover, because not all phenytoin-induced adverse events are attributed 
to HLA-B*15:02 or CYP2C9 metabolizer status, clinicians should carefully monitor all 
patients according to standard practices.
Caveats: Appropriate Use and/or Potential Misuse of Genetic Tests
The application of genotype-based dosing is most appropriate when initiating phenytoin 
therapy. Obtaining genetic information after months of drug therapy is less helpful, given 
that the drug dose may have already been adjusted based on plasma concentrations, 
response, or side effects. As with all diagnostic tests, genetic tests are only one of several 
pieces of clinical information that should be considered before initiating drug therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Algorithm for suggested clinical actions based HLA-B*15:02 and CYP2C9 genotype
EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer
aIf patient has previously used phenytoin for longer than 3 months without incidence of 
cutaneous adverse reactions, reinitiate phenytoin with caution. Adjust dose based on 
CYP2C9 genotype if known.
bCarbamazepine should not be used as an alternative (4). Alternative medications such as 
oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking 
SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing 
alternatives to phenytoin (see Supplement for details).
cRecommended maintenance dose based on patient’s clinical characteristics
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Table 1
Assignment of likely phenotype based on genotypes
Assignment of likely CYP2C9 phenotypes based on genotypes
Likely Phenotypea Genotypes Examples of diplotypes
Extensive metabolizer (normal activity) (constitutes ~ 91% of 
patients)
An individual carrying two normal activity 
alleles
*1/*1
Intermediate metabolizerc (heterozygote or intermediate activity) 
(constitutes ~ 8% of patients)
An individual carrying one normal activity 
allele plus one decreased function allele
*1/*3, *1/*2
Poor metabolizer (homozygous variant, mutant, low, or deficient 
activity) (constitutes ~ 1% of patients)
An individual carrying two decreased function 
alleles
*2/*2, *3/*3, *2/*3
Assignment of likely HLA-B phenotypes based on genotypes
Likely Phenotypeb Genotype Examples of diplotypes
Homozygous for an allele other than *15:02; at “normal” or 
reduced risk of phenytoin-associated cutaneous adverse 
reactions (constitutes ~ 98.6% of patients)
HLA-B*15:02 non-carrier. No *15:02 alleles 
reported, often reported as “negative” on a 
genotyping test.
*X/*Xd
Heterozygote or homozygous variant; at significantly 
increased risk of phenytoin-associated cutaneous adverse 
reactions (constitutes ~ 1.4% of patients)
HLA-B*15:02 Carrier. One or two *15:02 
alleles, often reported as “positive” on a 
genotyping test.
*15:02/*Xd, *15:02/*15:02
a,bGlobal frequencies presented in the parenthesis. Haplotype frequencies vary among populations, please see details for individual population 
frequencies in aSupplemental Table S5, S6 and S7 for CYP2C9*2 and *3, and bSupplemental Table S3 and S4 for HLA-B*15:02.
c
The enzyme activity in this grouping varies widely. See Supplemental Table S2 for activity ranges.
dWhere *X = any genotype other than *15:02
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